LifeArc and GVK BIO Celebrate a decade of Partnership

Partnership evolved from a tactical into a ‘Preferred Partner’

Over the decade focused on modulating novel targets with therapeutic potential in disease where there is patient need

Novel chemical entities discovered from the partnership advanced to clinical development

Shared goal of advancing novel research ideas into potential medicines to benefit patient

GVK BIO team has augmented LifeArc’s internal biology efforts, by supporting biochemical assays, carrying out drug metabolism and pharmacokinetics profiling studies

GVK BIO team will soon  be supporting in developing cell - based assays and running protein expressions and purification studies   

May 15, 2019, Mumbai, India/London, UK : GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, are pleased to announce the 10^th anniversary of a successful partnership. The collaboration between LifeArc and GVK BIO brings together two organizations with a singular vision: advancing novel research ideas into potential medicines that can make a significant difference to patients.

LifeArc’s novel approach involves levering partnerships with academia and leading service organizations to advance discoveries into promising medicines.  Over the past decade, LifeArc scientific teams have focused their efforts on modulating novel targets with therapeutic potential in diseases where there is patient need, with the GVK BIO team assisting in synthesizing complex molecules rapidly and cost effectively to drive iterative improvement in efficacy and safety.

Promising novel chemical entities discovered from this partnership have been either advanced by LifeArc into clinical development, or have been licensed out to leading global pharmaceutical companies, including a recently announced deal in neuroscience. As the partnership evolved from a tactical relationship into a preferred partnership, the GVK BIO team has augmented LifeArc’s internal biology efforts, by supporting biochemical assays, carrying out drug metabolism and pharmacokinetics profiling studies, and soon, will be developing cell-based assays and running protein expression and purification studies. 

“It has been our privilege to have collaborated with LifeArc and its world class team of scientists that have delivered medicines such as Keytruda®, Tysabri®, and Entyvio® among others”, said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO. “The longevity of this partnership, and the transformative results of the collaboration, serve as a testament to the capabilities of the GVK BIO team and its commitment to work with customers to make a difference in human life. We look forward to continuing this successful relationship with LifeArc in the coming years.”

Commenting on the partnership, Melanie Lee, Chief Executive Officer, LifeArc said:“At LifeArc, we’re committed to translating scientific innovation to benefit patients. Our partnership with GVK BIO is a strong example of how shared goals and collaboration can create real value.”

About GVK BIO: GVK BIO, a leading Contract Research & Development Organization servicing the global Biopharma industry; is headquartered in Hyderabad, India with operations in five sites including California, USA. Established in 2001, GVK BIO has over 18 years of experience across the Research and Development value chain with a focus on speed and quality while ensuring safety and compliance. GVK BIO’s team of over 2100 highly qualified scientists, backed by a no-conflict business model, well-defined and scalable processes, modern facilities, and a strong customer-centric partnering approach, focus on bringing its customers’ products to market.www.gvkbio.com

About LifeArc: LifeArc is a self-funded medical research charity.  Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We’ve been doing this for more than 25 years and our work has resulted in four licensed medicines and a diagnostic for antibiotic resistance. Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics facilities, supported by experts in technology transfer and intellectual property who also provide services to external clients. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and scientists. www.lifearc.org; Twitter @lifearc1